Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fetal haemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anaemia.

British journal of haematology - 1 Apr 2008

Kumkhaek Chutima, Taylor James G, Zhu Jianqiong, Hoppe Carolyn, Kato Gregory J, Rodgers Griffin P

Abstract excerpt

The hydroxycarbamide (HC)-inducible small guanosine triphosphate (GTP)-binding protein, secretion-associated and RAS-related (SAR) protein has recently been shown to play a pivotal role in HBG induction and erythroid maturation by causing cell apoptosis and G1/S-phase arrest. Our preliminary analysis indicated that HC inducibility is transcriptionally regulated by elements within the SAR1A promoter. This study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia, Sickle Cell
Share to Fetal Hemoglobin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to SCD gene

Share to Hydroxyurea

Share to Infant, Newborn

Share to Monomeric GTP-Binding Proteins

Share to Polymorphism, Single Nucleotide

Share to Promoter Regions, Genetic

Source

Open in PubMed Open full text

Identifiers

PMID: 18318767
DOI: 10.1111/j.1365-2141.2008.07045.x
PMCID: PMC2344124

Genes

SCD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fetal haemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anaemia.PMID 18318767Read ↗

Sequence change in the HS2-LCR and Ggamma-globin gene promoter region of sickle cell anemia patients.Semantic proximity Read ↗

SAR1a promoter polymorphisms are not associated with fetal hemoglobin in patients with sickle cell disease from Cameroon.Semantic proximity Read ↗

A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease.Semantic proximity Read ↗

Whole exome sequencing identifies novel genes for fetal hemoglobin response to hydroxyurea in children with sickle cell anemia.Semantic proximity Read ↗

Epigenetic and molecular profiles of erythroid cells after hydroxyurea treatment in sickle cell anemiaSemantic proximity Read ↗

Exploring pharmacogenetic factors influencing hydroxyurea response in tanzanian sickle cell disease patients: a genomic medicine approach.Semantic proximity Read ↗

Gene polymorphisms predicting response to hydroxyurea treatment in Bahraini patients with sickle cell disease.Semantic proximity Read ↗

Exploring Pharmacogenetic Factors Influencing Hydroxyurea Response in Tanzanian Sickle Cell Disease Patients: A Genomic Medicine ApproachSemantic proximity Read ↗

Emerging science of hydroxyurea therapy for pediatric sickle cell disease.Semantic proximity Read ↗

A genetic variation associated with plasma erythropoietin and a non-coding transcript of PRKAR1A in sickle cell disease.Semantic proximity Read ↗

Safety and efficacy study of CRISPR/Cas9 treatment of sickle cell disease in clinically relevant conditions highlights disease-specific responseSemantic proximity Read ↗

Reviewing the impact of hydroxyurea on DNA methylation and its potential clinical implications in sickle cell diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.